| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
B-Dependent Inflammatory Responses of Human Endothelial Cells and Macrophages to Atherogenic Stimuli1
,
* Rayne Laboratory, Medical Research Council Centre for Inflammation Research, Medical School, and
Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom;
Centre for Gene Therapeutics and Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada; and
University of Tromsø, Tromsø, Norway
Atherosclerosis is a chronic inflammatory disease affecting arterial vessels. Strategies to reduce the inflammatory responses of endothelial cells and macrophages may slow lesion development and prevent complications such as plaque rupture. The human protease human neutrophil elastase (HNE), oxidized low density lipoprotein, LPS, and TNF-
were chosen as model stimuli of arterial wall inflammation and led to production of the chemokine IL-8 in endothelial cells. To counteract the activity of HNE, we have examined the effects of adenoviral gene delivery of the anti-elastases elafin, previously demonstrated within human atheroma, and murine secretory leukocyte protease inhibitor (SLPI), a related molecule, on the inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli. We developed a technique of precomplexing adenovirus with cationic lipid to augment adenoviral infection efficiency in endothelial cells and to facilitate infection in macrophages. Elafin overexpression protected endothelial cells from HNE-induced IL-8 production and cytotoxicity. Elafin and murine SLPI also reduced endothelial IL-8 release in response to oxidized low density lipoprotein, LPS, and TNF- and macrophage TNF- production in response to LPS. This effect was associated with reduced activation of the inflammatory transcription factor NF-
B, through up-regulation of IB, in both cell types. Our work suggests a novel and extended anti-inflammatory role for these HNE inhibitors working as effectors of innate immunity to protect tissues against maladaptive inflammatory responses. Our findings indicate that elafin and SLPI may be gene therapy targets for the treatment of atheroma.
This article has been cited by other articles:
|
|
 |
|
  T. S. Wilkinson, K. Dhaliwal, T. W. Hamilton, A. F. Lipka, L. Farrell, D. J. Davidson, R. Duffin, A. C. Morris, C. Haslett, J. R.W. Govan, et al. Trappin-2 Promotes Early Clearance of Pseudomonas aeruginosa through CD14-Dependent Macrophage Activation and Neutrophil Recruitment Am. J. Pathol., April 1, 2009; 174(4): 1338 - 1346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Guyot, M. W. Butler, P. McNally, S. Weldon, C. M. Greene, R. L. Levine, S. J. O'Neill, C. C. Taggart, and N. G. McElvaney Elafin, an Elastase-specific Inhibitor, Is Cleaved by Its Cognate Enzyme Neutrophil Elastase in Sputum from Individuals with Cystic Fibrosis J. Biol. Chem., November 21, 2008; 283(47): 32377 - 32385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W Horne, S. J Stock, and A. E King Innate immunity and disorders of the female reproductive tract Reproduction, June 1, 2008; 135(6): 739 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. Samsom, A. P. J. van der Marel, L. A. van Berkel, J. M. L. M. van Helvoort, Y. Simons-Oosterhuis, W. Jansen, M. Greuter, R. L. H. Nelissen, C. M. L. Meeuwisse, E. E. S. Nieuwenhuis, et al. Secretory Leukoprotease Inhibitor in Mucosal Lymph Node Dendritic Cells Regulates the Threshold for Mucosal Tolerance J. Immunol., November 15, 2007; 179(10): 6588 - 6595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Roghanian, E. M. Drost, W. MacNee, S. E. M. Howie, and J.-M. Sallenave Inflammatory Lung Secretions Inhibit Dendritic Cell Maturation and Function via Neutrophil Elastase Am. J. Respir. Crit. Care Med., December 1, 2006; 174(11): 1189 - 1198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Wang, T. Thuraisingam, L. Fallavollita, A. Ding, D. Radzioch, and P. Brodt The Secretory Leukocyte Protease Inhibitor Is a Type 1 Insulin-Like Growth Factor Receptor-Regulated Protein that Protects against Liver Metastasis by Attenuating the Host Proinflammatory Response. Cancer Res., March 15, 2006; 66(6): 3062 - 3070. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Murata, M. Hori, S. Lee, A. Nakamura, K. Kohama, H. Karaki, and H. Ozaki Vascular Endothelium Has a Local Anti-Adenovirus Vector System and Glucocorticoid Optimizes Its Gene Transduction Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1796 - 1803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. McMichael, A. I. Maxwell, K. Hayashi, K. Taylor, W. A. Wallace, J. R. Govan, J. R. Dorin, and J.-M. Sallenave Antimicrobial Activity of Murine Lung Cells against Staphylococcus aureus Is Increased In Vitro and In Vivo after Elafin Gene Transfer Infect. Immun., June 1, 2005; 73(6): 3609 - 3617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. K. Jana, L. R. Gray, and D. C. Shugars Human Immunodeficiency Virus Type 1 Stimulates the Expression and Production of Secretory Leukocyte Protease Inhibitor (SLPI) in Oral Epithelial Cells: a Role for SLPI in Innate Mucosal Immunity J. Virol., May 15, 2005; 79(10): 6432 - 6440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. I. Brown, R. Mistry, D. D. Collie, S. Tate, and J.-M. Sallenave Trappin ovine molecule (TOM), the ovine ortholog of elafin, is an acute phase reactant in the lung Physiol Genomics, September 16, 2004; 19(1): 11 - 21. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
